<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136303">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02078180</url>
  </required_header>
  <id_info>
    <org_study_id>HHSF223201310164C</org_study_id>
    <secondary_id>HUM00081894</secondary_id>
    <nct_id>NCT02078180</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns</brief_title>
  <official_title>Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this project are to determine if the bioavailability and release pattern
      of bupropion HCl products differ and if the genotype of the metabolic enzymes affects the
      saturation of intestinal enzymes with different dose strengths within one product line.
      Findings from this project will help the FDA Center for Drug Evaluation and Research's
      (CDER) Office of Generic Drugs improve policy development and review practice in the future
      for similar products, e.g. extended release oral drug products being metabolized in the gut
      wall and having multiple strengths.

      Aim 1: To compare the pharmacokinetics of bupropion and its metabolites in plasma in healthy
      individuals when they ingest different strengths of bupropion (75-300 mg) with variable
      release profiles (IR vs XL vs SR) in GI tract.

      Working hypothesis: Variation in release rate and mechanism of bupropion formulations in
      gastrointestinal (GI) tract will impact metabolism and saturation of bupropion in GI tract,
      which will generate different concentration of bupropion and its metabolites in plasma.

      Aim 2: To investigate pharmacogenomics of CYP 2B6 that influences metabolism, saturation,
      and pharmacokinetics of bupropion

      Working hypothesis: The gain of function of CYP2B6 variants (allele *4 and *22)  in patients
      will increase the metabolism of bupropion in the GI tract and liver, reduce both local
      concentration and plasma concentration of bupropion, and thus cause non-bioequivalence when
      bupropion is released earlier in GI tract
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>PK parameters for bupropion formulations: half-life (t1/2), volume of distribution (Vd/F), oral clearance (CL/F), maximum drug concentration (Cmax), time to reach Cmax (Tmax), area under the concentration vs. time curve (AUC), absorption rate constant</measure>
    <time_frame>Pharmacokinetic (PK) data will be collected over time points:  0, 0.5, 1, 2, 3, 4, 6, 8, 12*, 24, 48, 72, and 96 hours post-dose. *XL formulation only.</time_frame>
    <safety_issue>No</safety_issue>
    <description>For each drug formulation we will collect a PK sample at each time point.  We will use this composite of data (all time points for each formulation) to model Pharmacokinetic parameters such as half-life (t1/2), volume of distribution (Vd/F), oral clearance (CL/F), maximum drug concentration (Cmax), time to reach Cmax (Tmax), area under the concentration vs. time curve (AUC), absorption rate constant.  However, we will do each formulation separately (not as a composite).</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>generic bupropion IR75</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One oral dose of generic bupropion IR75</description>
  </arm_group>
  <arm_group>
    <arm_group_label>generic bupropion IR100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One oral dose of generic bupropion IR100</description>
  </arm_group>
  <arm_group>
    <arm_group_label>generic bupropion SR100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One oral dose of generic bupropion SR100</description>
  </arm_group>
  <arm_group>
    <arm_group_label>generic bupropion SR150</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One oral dose of generic bupropion SR150</description>
  </arm_group>
  <arm_group>
    <arm_group_label>generic bupropion XL150</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One oral dose of generic bupropion XL150</description>
  </arm_group>
  <arm_group>
    <arm_group_label>generic bupropion XL300</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One oral dose of generic bupropion XL300</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>generic bupropion</intervention_name>
    <arm_group_label>generic bupropion IR75</arm_group_label>
    <arm_group_label>generic bupropion IR100</arm_group_label>
    <arm_group_label>generic bupropion SR100</arm_group_label>
    <arm_group_label>generic bupropion SR150</arm_group_label>
    <arm_group_label>generic bupropion XL150</arm_group_label>
    <arm_group_label>generic bupropion XL300</arm_group_label>
    <other_name>Wellbutrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers 25 to 55 years old.

          -  Volunteers have a Body Mass Index (BMI), calculated from the ratio of height and
             weight, within a range of 18.5 to 35.

          -  Willing to be medication and supplement free 2 weeks prior to beginning study, and
             throughout the study. All forms of birth control are okay.

        Exclusion Criteria:

          -  Individuals unwilling or unable to comply with the study protocol (e.g. unable to
             remain medication or supplement free during the study).

          -  Individuals unwilling or unable to take bupropion or have an allergy to bupropion

          -  Any medical or surgical conditions which might significantly alter bupropion
             absorption (e.g., history of malabsorption, liver disease, gastric bypass surgery )

          -  Individuals with a history of psychiatric or neurological illness, including seizure
             disorders

          -  Nicotine dependence

          -  Alcohol dependence

          -  Pregnant or nursing women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duxin Sun, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gloria Harrington</last_name>
    <phone>877-864-3637</phone>
    <email>bpresearch@umich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-2700</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>February 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Duxin Sun</investigator_full_name>
    <investigator_title>Professor of Pharmaceutical Sciences</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
